Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers G > Headlines for Gilead Sciences Inc. > News item |
Gilead Sciences retained by Merrill at neutral
Gilead Sciences Inc. was retained by Merrill Lynch analyst Eric Ende at a neutral rating following news that its second formulation of the fixed-dose, triplet combination of Truvada and Sustiva failed to demonstrate bioequivalence. Gilead shares Wednesday were down $1.13, or 2.65%, at $41.55 on volume of 9,699,832 shares versus the three-month running average of 3,742,980 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.